LONDON – Research and health emerged as the biggest losers following a marathon four days of negotiations by EU leaders on the bloc’s €1.1 trillion (US$1.3 trillion) 2021 - 2027 budget and the formation of a €750 billion (US$872 billion) pandemic recovery fund. Rather than €94.4 billion over the next seven years as proposed, the R&D program Horizon Europe, will get €80.9 billion.
With no new cases reported for more than 100 days, Taiwan appears to have successfully contained the spread of COVID-19 and has drawn attention to its medical achievements. Experts said at BIO Asia-Taiwan conference this week that with continuous government and investor support, the East Asian nation could move further up to join other leading biotech players.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aptorum, Arcturus, Cel-Sci, Fujifilm, Hansoh, Menarini, Novavax, Protalix, Radius, Sarcomed, Sareum, Sorrento, Smartpharm, Tissue Regenix.
In the shadow of COVID-19, experts at the BIO Asia-Taiwan conference on Wednesday warned of present and future challenges for the biotech industry. Changes in manufacturing logistics and financial distress will continue to cause concern for the industry.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adial, Cymabay, Elsalys, Inotrem, Milestone, Neumentum, Vita.
RSS
